Novo’s Wegovy Pill Fuels Higher Danish Economic Growth Forecast

Denmark's government raised its 2026 economic growth forecast for the fourth time, citing a larger-than-expected contribution from Novo Nordisk's oral weight-loss medication. The Danish pharmaceutical company's pill version of its weight-loss drug entered the market and generated higher-than-anticipated sales and tax revenue. Denmark's economic forecasting agency attributed the upward revision to increased pharmaceutical export revenue and related economic activity.

Next story